TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30481495

Group type: EXPERIMENTAL
Intervention: Online care
Number of subjects: 296

Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 296
Study: 27734072

Group type: EXPERIMENTAL
Intervention: Platelet microparticle assay (PMA)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Argatroban therapy initiated on the same day
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Argatroban therapy delayed by one or more days
Number of subjects: 401
Study: 25577176

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) administration
Number of subjects: 23
Study: 24772726

Group type: EXPERIMENTAL
Intervention: Probiotic formulation containing Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17110467

Group type: EXPERIMENTAL
Intervention: Olive oil with high phenolic content
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Olive oil with medium phenolic content
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Olive oil with low phenolic content
Number of subjects: 182
Study: 15220012

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg QD initially, titrated to max 45 mg)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Glimepiride (2 mg QD initially, titrated to max 8 mg)
Number of subjects: 244
Study: 11527474

Group type: EXPERIMENTAL
Intervention: rhGH administered subcutaneously daily at bedtime
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhGH and a structured resistance exercise program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Structured resistance exercise with placebo injections
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo injections only
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined rhGH treated subjects
Number of subjects: 31
Study: 9239456

Group type: EXPERIMENTAL
Intervention: Test patch (MenorestTM) at 37.5 micrograms E2/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test patch (MenorestTM) at 50 micrograms E2/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test patch (MenorestTM) at 75 micrograms E2/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference patch at 50 micrograms E2/day
Number of subjects: 24
Study: 8498761

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including foot-care education, behavioral contracts, and reminders.
Number of subjects: 352
Study: 3102323

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (600 mg/100 ml) by enema
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prednisolone (20 mg/100 ml) by enema
Number of subjects: 70
Study: 4932544

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (200 mg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 54
Study: 31957417

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel (CG gel)
Number of subjects: 30
Study: 30418491

Group type: EXPERIMENTAL
Intervention: Early Social Interaction (ESI) model
Number of subjects: 82
Study: 27709225

Group type: EXPERIMENTAL
Intervention: Acarbose (20-week treatment)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (24-week treatment on top of metformin)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 79
Study: 25257865

Group type: EXPERIMENTAL
Intervention: Skim milk (SM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Carbohydrate‐electrolyte solution (CES)
Number of subjects: 28
Study: 22094635

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM coadministered with routine vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine vaccinations alone
Number of subjects: 0
Study: 20301825

Group type: EXPERIMENTAL
Intervention: 15-cm multiholed catheter
Number of subjects: 16

Group type: COMPARATOR
Intervention: triple-orifice epidural catheter
Number of subjects: 16
Study: 17709295

Group type: EXPERIMENTAL
Intervention: 1000 mg levetiracetam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 mg topiramate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16285598

Group type: EXPERIMENTAL
Intervention: Restorations carried out immediately after bleaching (T0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restorations 7 days after bleaching (T7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restorations 14 days after bleaching (T14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restorations 21 days after bleaching (T21)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group - restorations in unbleached teeth (TC)
Number of subjects: 0
Study: 12042580

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for infants and 20 mg for older children)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study: 10442852

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (3.0 mg/kg over 5 min, followed by 30 microg/kg/min over 75 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (6.0 mg/kg over 5 min, followed by 60 microg/kg/min over 75 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous endothelin-1 (ET-1; 5.0 ng/kg/min for 80 min)
Number of subjects: 0
Study: 8674563

Group type: EXPERIMENTAL
Intervention: 1.2 g of Augmentin (co‐amoxiclav) i.v. at induction of anaesthesia
Number of subjects: 116

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 116
Study: 2190041

Group type: EXPERIMENTAL
Intervention: Verapamil, 320 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ethmosine, 800 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ethacizine, 150 mg/day
Number of subjects: 27
Study: 32799

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5, 1, 2, 4, 8 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Pentobarbital (100 mg)
Number of subjects: 240
Study: 30916575

Group type: EXPERIMENTAL
Intervention: Human milk (Prolacta Bioscience, Duarte, CA) administered from day -3 until day +14 after BMT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard formula (control group)
Number of subjects: 46
Study: 28551058

Group type: EXPERIMENTAL
Intervention: remifentanil-desflurane (REM-DES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: remifentanil-propofol (REM-PRO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (REM-PRO and REM-DES)
Number of subjects: 40
Study: 26264722

Group type: EXPERIMENTAL
Intervention: Walking speed assessed by the Timed 25‐Foot Walk
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Walking (speed, endurance, dexterity)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Unemployed participants
Number of subjects: 52
Study: 24276097

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) applied to open fractures in the 2008-2009 cohort.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusive dressing applied to open fractures in the 2003-2004 cohort.
Number of subjects: 0
Study: 21395905

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Proluton depot
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 150
Study: 19731848

Group type: EXPERIMENTAL
Intervention: Inhalation of 70% isopropyl alcohol (IPA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: IV promethazine
Number of subjects: 85
Study: 17909211

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skeletal muscle relaxants (for acute low back pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (for chronic low back pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin (for radiculopathy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 0
Study: 15081650

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 403

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 403
Study: 11523603

Group type: EXPERIMENTAL
Intervention: Linear approach (25 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Focal approach (25 patients)
Number of subjects: 50
Study: 9566477

Group type: EXPERIMENTAL
Intervention: Fluvoxamine, 150mg/day
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Citalopram, 20mg/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: No pharmacological treatment (Control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 81
Study: 7816261

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CsA) treatment at a mean dose of 3.23 mg/kg/day for 12 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CsA) treatment
Number of subjects: 10
Study: 2975147

Group type: COMPARATOR
Intervention: Thiopental alone (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thiopental and ketamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thiopental and isoflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thiopental and NLA drugs
Number of subjects: 24
Study: 31845487

Group type: EXPERIMENTAL
Intervention: Nasal masks (NM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nasal prongs (NP)
Number of subjects: 80
Study: 28926296

Group type: EXPERIMENTAL
Intervention: Urokinase (100,000 IU, three doses, 12-hourly)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 26924265

Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2000 IU of vitamin D
Number of subjects: 60
Study: 25796007

Group type: EXPERIMENTAL
Intervention: Heavy drinking (HD) group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups after one month of abstinence
Number of subjects: 38
Study: 23073171

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) supplementation (3g daily for 30 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PLC) supplementation (3g daily for 30 days)
Number of subjects: 18
Study: 21626077

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) nicardipine initiated within 3 hours of onset of ICH and continued for the next 24 hours
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Standard SBP reduction to ≤180 mm Hg
Number of subjects: 1280
Study: 18482628

Group type: EXPERIMENTAL
Intervention: Inotropes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasoactive medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study: 16634837

Group type: EXPERIMENTAL
Intervention: B‐vitamins (50 mg thiaminhydrochlorid, 50 mg pyridoxine, and 0.05 mg cyanocobalamin), plus 5 mg folic acid daily for 6 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: B‐vitamins
Number of subjects: 65
Study: 12806859

Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual risk profile assessment
Number of subjects: 0
Study: 10877152

Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study: 9663826

Group type: EXPERIMENTAL
Intervention: Intravenous standard heparin (subcutaneous in two patients), adjusted to provide standard anticoagulant activity.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heparin (second occasion during a relapse)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heparin (general treatment)
Number of subjects: 16
Study: 1541605

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study: 4011073

Group type: EXPERIMENTAL
Intervention: X-ray pelvimetry
Number of subjects: 200

Group type: COMPARATOR
Intervention: No x-ray pelvimetry
Number of subjects: 200
Study: 31924334

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 26
Study: 31309968

Group type: EXPERIMENTAL
Intervention: Ratings of Perceived Difficulty (RPD) scales
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Numerical RPD scale
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Postural sway measures
Number of subjects: 62
Study: 28292754

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1764

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1764
Study: 25595195

Group type: EXPERIMENTAL
Intervention: Acupuncture at PC6, HT7 and LR3 for 10 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control group (no intervention initially)
Number of subjects: 40
Study: 23250818

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 12 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21883644

Group type: EXPERIMENTAL
Intervention: PRP&D/P MPs
Number of subjects: 26

Group type: COMPARATOR
Intervention: PRP and saline (control)
Number of subjects: 26
Study: 19700934

Group type: EXPERIMENTAL
Intervention: Aeroneb-go (AE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Omron-NE-U22 (OM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pari-eMotion (PA)
Number of subjects: 36
Study: 17989384

Group type: EXPERIMENTAL
Intervention: Three cycles of MOPP-ABV plus involved-field radiotherapy
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Subtotal nodal radiotherapy alone
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Six cycles of MOPP-ABV plus involved-field radiotherapy
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Four cycles of MOPP-ABV plus involved-field radiotherapy
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Four cycles of MOPP-ABV plus subtotal nodal radiotherapy
Number of subjects: 1538
Study: 14519707

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study: 10534147

Group type: EXPERIMENTAL
Intervention: Chinese medicinal herbs (seven pills containing a standardized preparation of 35 Chinese herbs, four daily doses for 6 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Chinese medicinal herbs
Number of subjects: 68
Study: 8980932

Group type: EXPERIMENTAL
Intervention: Omeprazole/Amoxycillin (n = 11)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Omeprazole/Amoxycillin/Metronidazole (n = 16)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Subcitrate/Amoxycillin/Metronidazole (n = 11)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Follow-up at 2 years
Number of subjects: 38
Study: 1871692

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study: 7159001

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 130

Group type: COMPARATOR
Intervention: Clindamycin-gentamycin combination
Number of subjects: 130
Study: 6202746

Group type: EXPERIMENTAL
Intervention: Disposable fabric operating clothing (Barrier 450, Johnson & Johnson)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional cotton clothing
Number of subjects: 52
Study: 28345173

Group type: EXPERIMENTAL
Intervention: 10% increase in step rate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 10% decrease in step rate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5% change in step rate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Preferred step rate
Number of subjects: 32
Study: 27466220

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 25
Study: 25571338

Group type: EXPERIMENTAL
Intervention: Tizanidine (α2-adrenergic agonist), administered over a 4-week program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline walking endurance
Number of subjects: 0
Study: 22748458

Group type: EXPERIMENTAL
Intervention: Bundle treatment
Number of subjects: 203
Study: 19937077

Group type: EXPERIMENTAL
Intervention: Lichtenstein group (LG)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mesh plug group (MPG)
Number of subjects: 64
Study: 18195164

Group type: EXPERIMENTAL
Intervention: Low-fat diet (30% fat calories)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-carbohydrate diet (20 g of carbohydrates)
Number of subjects: 20
Study: 16393753

Group type: EXPERIMENTAL
Intervention: Left emotional faces
Number of subjects: 5

Group type: COMPARATOR
Intervention: Left neutral faces
Number of subjects: 5
Study: 14598195

Group type: EXPERIMENTAL
Intervention: Electronic pedometer placed at the front of the waist
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Electronic pedometer placed at the side of the waist
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Electronic pedometer placed at the back of the waist
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hand-tally counter (reference)
Number of subjects: 66
Study: 10792114

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 microg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8852095

Group type: EXPERIMENTAL
Intervention: Information programme consisting of a group meeting and a brochure
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 128
Study: 1734572

Group type: EXPERIMENTAL
Intervention: Epidural morphine sulfate (EPI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intramuscular morphine sulfate (IM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Patient controlled morphine sulfate (PCA)
Number of subjects: 68
Study: 6734037

Group type: EXPERIMENTAL
Intervention: Nalbuphine (30 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Combination of nalbuphine (30 mg) and acetaminophen (650 mg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 30787075

Group type: EXPERIMENTAL
Intervention: Tobacco, Exercise and dieT MEssages programme (4 text messages per week for 6 months)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Tobacco, Exercise and dieT MEssages programme
Number of subjects: 683

Group type: COMPARATOR
Intervention: Control group (no text messaging intervention)
Number of subjects: 683
Study: 29463159

Group type: EXPERIMENTAL
Intervention: Hydrofilm polyurethane film dressings
Number of subjects: 62

Group type: COMPARATOR
Intervention: 5% urea lotion
Number of subjects: 62
Study: 27002667

Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT) program, 5 sessions per week for 6 weeks, in addition to conventional rehabilitation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 26
Study: 24677110

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% four times daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eight times daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 110
Study: 22560713

Group type: EXPERIMENTAL
Intervention: 50.4 Gy radiotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Up-front temozolomide
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Digital ICR
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Digital RT plan submission and review
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 57
Study: 20978259

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 579
Study: 18482101

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Tolcapone (switch from entacapone)
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Entacapone (switch from tolcapone)
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2566
Study: 16050943

Group type: EXPERIMENTAL
Intervention: Pramlintide (0.1-1 mg daily or 0.1-0.8 mg four times a day for 5 or 6 days)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pramlintide (30, 100 or 300 microg three times daily for 14 days)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pramlintide (various doses as mentioned)
Number of subjects: 3
Study: 14763223

Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) (Arlevert [ARL])
Number of subjects: 82

Group type: COMPARATOR
Intervention: Betahistine dimesylate (12 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine and dimenhydrinate (ARL)
Number of subjects: 82
Study: 10360138

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 8952010

Group type: EXPERIMENTAL
Intervention: Vigabatrin 2 g/day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vigabatrin 3 g/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97